GlassScriptPhysician profile
Corey T Rammell
NPI 1013008697
$1,583.09
in general payments reported to CMS, 2019-2025
24 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $112 · 2021: $374 · 2022: $278 · 2023: $287 · 2024: $194 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $539.08 | 2021-2025 | |
| Amgen INC. | $211.22 | 2019-2023 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $160.83 | 2019-2023 | Spravato |
| Novo Nordisk INC | $106.23 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $81.83 | 2019-2023 | Mounjaro |
| Stryker Corporation | $68.90 | 2023 | Inbone |
| Ultragenyx Pharmaceutical INC. | $57.33 | 2021-2022 | |
| Boston Scientific Corporation | $40.80 | 2021-2025 | General - Pain Management |
| Astellas Pharma US INC | $32.16 | 2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $30.33 | 2020-2021 | |
| Flowonix Medical Incorporated | $26.86 | 2020 | |
| Kyowa Kirin, INC. | $24.98 | 2023 | Crysvita |
| Viatris Specialty LLC | $21.44 | 2025 | Yupelri |
| Allergan, INC. | $19.94 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.51 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $18.23 | 2019 | |
| Mylan Specialty L.P. | $18.19 | 2022 | |
| Medtronic, INC. | $17.64 | 2025 | Inceptiv |
| Alnylam Pharmaceuticals INC. | $17.25 | 2023 | Amvuttra |
| Arbor Pharmaceuticals, INC. | $15.16 | 2020 | |
| Edwards Lifesciences Corporation | $14.93 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Takeda Pharmaceuticals U.S.A., INC. | $14.41 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.17 | 2022 | |
| Glaxosmithkline, LLC. | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Rammell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.